Merete B Long, Hani Abo-Leyah, Yan Hui Giam, Thenmalar Vadiveloo, Rebecca C Hull, Holly R Keir, Thomas Pembridge, Daniela Alferes De Lima, Lilia Delgado, Sarah K Inglis, Chloe Hughes, Amy Gilmour, Marek Gierlinski, Benjamin J M New, Graeme MacLennan, Albena T Dinkova-Kostova, James D Chalmers
INTRODUCTION: Sulforaphane can induce the transcription factor, Nrf2, promoting antioxidant and anti-inflammatory responses. In this study, hospitalised patients with community-acquired pneumonia (CAP) were treated with stabilised synthetic sulforaphane (SFX-01) to evaluate impact on clinical status and inflammation. METHODS: Double-blind, randomised, placebo-controlled trial of SFX-01 (300 mg oral capsule, once daily for 14 days) conducted in Dundee, UK, between November 2020 and May 2021...
March 2024: ERJ Open Research